2,2,6-三甲基-4-哌啶基苯甲酸酯 | 500-34-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2,2,6-三甲基-4-哌啶基苯甲酸酯
• 英文名称: 4,4-Benzoxy-2,2,6-trimethyl-piperidin
• 英文别名: 4-Benzoxy-2,2,6-trimethyl-piperidin；β-Eucain；β-Isoeucain；benzoic acid-(2,2,6-trimethyl-[4]piperidyl ester)；Benzoesaeure-(2,2,6-trimethyl-[4]piperidylester)；betacaine；beta-Eucaine；(2,2,6-trimethylpiperidin-4-yl) benzoate
• CAS: 500-34-5
• 化学式: C₁₅H₂₁NO₂
• 分子量: 247.337
• InChiKey: ZYHGIAPHLSTGMX-UHFFFAOYSA-N

物化性质

• 熔点：
  70-71° (corr)
• 沸点：
  390.37°C (rough estimate)
• 密度：
  1.0267 (rough estimate)
• 保留指数：
  1820;1816

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Nitric Oxide Releasing Prodrugs of Therapeutic Agents
  申请人：SATYAM Apparao

  公开号：US20110263526A1

  公开（公告）日：2011-10-27

  The present invention relates to nitric oxide releasing prodrugs of known drugs or therapeutic agents which are represented herein as compounds of formula (I) wherein the drugs or therapeutic agents contain one or more functional groups independently selected from a carboxylic acid, an amino, a hydroxyl and a sulfhydryl group. The invention also relates to processes for the preparation of the nitric oxide releasing prodrugs (the compounds of formula (I)), to pharmaceutical compositions containing them and to methods of using the prodrugs.

  本发明涉及已知药物或治疗剂的一氧化氮释放前药，其在此处表示为式(I)的化合物，其中药物或治疗剂包含一个或多个功能基团，独立地选自羧酸、氨基、羟基和巯基。该发明还涉及制备一氧化氮释放前药（式(I)的化合物）的方法，含有它们的药物组合物以及使用这些前药的方法。
• Technology for the Preparation of Microparticles
  申请人：Malakhov Michael

  公开号：US20090098207A1

  公开（公告）日：2009-04-16

  Microspheres are produced by contacting a solution of a macromolecule or small molecule in a solvent with an antisolvent and a counterion, and chilling the solution. The microspheres are useful for preparing pharmaceuticals, nutraceuticals, cosmetic products and the like of defined dimensions.

  微球是通过将溶液中的大分子或小分子与抗溶剂和对离子接触，并冷却溶液而制备的。这些微球可用于制备具有明确定义尺寸的药物、营养保健品、化妆品等产品。
• Compositions and methods to effect the release profile in the transdermal administration of active agents
  申请人：——

  公开号：US20020004065A1

  公开（公告）日：2002-01-10

  Compositions and methods for the transdermal delivery of active agents up to a period of seven days or more at substantially a zero-order release rate comprising a pharmaceutically acceptable adhesive matrix and a polymeric plastic material that provides a release rate regulating effect on the active agents.

  本发明涉及一种用于经皮递送活性药剂的组合物和方法，该组合物和方法能够在持续时间为七天或更长时间内以几乎零阶释放速率递送活性药剂，包括一种药学上可接受的粘合基质和一种聚合物塑料材料，该聚合物塑料材料对活性药剂具有释放速率调节作用。
• [EN] CROSS-LINKED HYALURONIC ACID GRAFTED WITH DEXTRAN<br/>[FR] ACIDE HYALURONIQUE RÉTICULÉ GREFFÉ À DU DEXTRANE
  申请人：GALDERMA SA

  公开号：WO2015181369A1

  公开（公告）日：2015-12-03

  A hyaluronic acid product is comprising a cross-linked hyaluronic acid and one or more dextran molecules. The hyaluronic acid is cross-linked by ether bonds, and the one or more dextran molecules are covalently grafted to the cross-linked hyaluronic acid.

  一种透明质酸产品，包括交联的透明质酸和一个或多个右旋糖酐分子。透明质酸通过醚键交联，一个或多个右旋糖酐分子通过共价接枝到交联的透明质酸上。
• Coated surgical needles
  申请人：Tyco Healthcare Group LP

  公开号：EP1813295A2

  公开（公告）日：2007-08-01

  The present disclosure relates to surgical needles having a coating thereon, the coating formed from a coating composition comprising at least one anesthetic material.

  本公开涉及具有涂层的手术针头，涂层由包含至少一种麻醉材料的涂层组合物形成。

表征谱图